Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin-Reference-Cited by-同舟云学术

Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin

Published:2021-07-31 Issue:11 Volume:100 Page:2727-2732
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Reinert Jochim^ORCID,Beitzen-Heineke Antonia,Wethmar Klaus,Stelljes Matthias,Fiedler Walter,Schwartz Stefan

Abstract

AbstractTreatment options for relapsed or refractory B-lymphoblastic leukaemia (r/r B-ALL) are limited and the prognosis of these patients remains dismal, but novel immunotherapeutic options such as the anti-CD22 antibody–drug-conjugate Inotuzumab-Ozogamicin (InO) have improved outcomes in these patients. Flow cytometry is essential to assess antigen-expression prior to treatment initiation of antigen-directed immunotherapies. Here, we present flow cytometric and clinical data of three adult patients with r/r B-ALL who failed treatment with InO associated with reduced or lost antigen-expression. In addition, we present comparative data on two different diagnostic CD22-specific antibody clones that exhibit significant differences in staining intensities.

Funder

Universitätsklinikum Hamburg-Eppendorf (UKE)

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-021-04601-0.pdf

Reference20 articles.

1. Hm K, Dj D, Stelljes M, Liedtke M, Stock W, Gökbuget N, O’brien Sm, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani As, (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 Ino-Vate study. Cancer 125(14):2474–2487. https://doi.org/10.1002/Cncr.32116

2. Stelljes M, Raffel S, Wäsch R, Scholl S, Kondakci M, Rank A, Haenel M, Martin S, Schwab K, Knaden J, Wethmar K, Sauer T, We B, Lenz G, Dugas M, Brüggemann M, Goekbuget N, Alakel N (2020) First results of an open label phase II study to evaluate the efficacy and safety of inotuzumab ozogamicin for induction therapy followed by a conventional chemotherapy based consolidation and maintenance therapy in patients aged 56 years and older with acute lymphoblastic leukemia (Initial-1 trial). Blood 136(Supplement 1):12–13. https://doi.org/10.1182/Blood-2020-136920

3. Kantarjian Hm SuY, Ej J, Bhattacharyya H, Yan E, Jc C, Di M (2018) Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer 124(10):2151–2160. https://doi.org/10.1002/Cncr.31317